ClinicalTrials.gg
Not yet recruitingNCT07263048Updated Nov 18, 2026

PrEP & Soccer: A Program for Pharmacy Chains to Increase PrEP Awareness and Access Among Men

An interventional study of PrEP & Soccer PrEP Navigation and CVS Health brochure in HIV Prevention, Latino Men Who Have Sex With Men and Pharmacy, sponsored by University of Miami. Not yet recruiting at 1 site in United States. Open to male participants aged 18 Years to 54 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of Miami · Not applicable, Interventional, and Prevention

How we know

Updated Nov 18, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
800
Allocation
Randomized
Ages
18 Years to 54 Years
Sex
Male
01

Study summary

This type 3 Hybrid Effectiveness-Implementation study will evaluate PrEP \& Soccer, a multicomponent and multilevel implementation strategy delivered by a pharmacy chain to increase PrEP knowledge and initial PrEP appointment attendance among men. Using mixed methods and implementation science approaches, this parallel cluster randomized controlled study will assess key implementation factors at CVS Health pharmacy locations assigned either to the PrEP \& Soccer intervention or to a general CVS Health service information-only control.

02

Conditions studied

  • HIV Prevention
  • Latino Men Who Have Sex With Men
  • Pharmacy
03

In context

Lead sponsor

University of Miami is the lead sponsor of 843 studies on the registry; 166 are open to participants now.

Of its 115 completed or terminated interventional studies of FDA-regulated products, 97 (84%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 54 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide their to participate.
  • Demonstrate willingness to comply with all study procedures and be available for the study duration.
  • Ages 18 to 54 years of age.
  • A man.
  • Self-report any of the following behaviors and/or health conditions

    1. Diagnosed with bacterial sexually transmitted infection (e.g., syphilis, gonorrhea, or chlamydia)
    2. Sex with a partner who is living with
    3. Sex without a condom with two or more partners whose HIV status were unknown
    4. Injection drug use and sharing injection equipment
  • Have been without a PrEP prescription for at least 24 weeks.

Exclusion criteria

Exclusion Criteria:

  • Diminished capacity to consent due to:

    1. Inability to provide (e.g., cognitive impairment), or
    2. Presence of severe psychiatric symptoms (e.g., mania, psychosis) that impair the ability to provide informed consent, as assessed by interviewers trained in CITI Human Subjects Research and NIH Good Clinical Practice.
  • Younger than 18 or older than 54 years of age.
  • A woman.
  • Does not self-report any of the following behaviors and/or health conditions

    1. Diagnosed with bacterial sexually transmitted infection (e.g., syphilis, gonorrhea, or chlamydia)
    2. Sex with a partner who is living with
    3. Sex without a condom with two or more partners whose HIV status were unknown
    4. Injection drug use and sharing injection equipment
  • Has had an active PrEP prescription within the past 24 weeks.
  • Living with HIV (e.g. has received an HIV diagnosis).
  • Planning to move outside of Miami-Dade or Broward counties in the next 7 months.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
800 participants (estimated)

Study arms

  • Experimental
    PrEP & Soccer Intervention

    Pharmacies assigned to "PrEP \& Soccer" group will receive personalized PrEP navigation support from the PrEP Navigator.

    Behavioral: PrEP & Soccer PrEP Navigation

  • Active comparator
    Standard of care (CVS standard health information)

    Pharmacies assigned to the control group will receive a brochure describing services offered by CVS Health and the MinuteClinic.

    Behavioral: CVS Health brochure

Interventions

  • BehavioralPrEP & Soccer PrEP Navigation

    Pharmacies assigned to this group will receive personalized PrEP navigation support provided by a PrEP Navigator following baseline assessment. Sessions may be brief (\~15 minutes) or longer depending on participant needs. The navigator supplies a pamphlet describing PrEP (how it works, payment options), and CVS-provided HIV services; discusses whether PrEP or another HIV prevention strategy is best for the participant; and, if PrEP is selected, provides a referral to a PrEP provider.

  • BehavioralCVS Health brochure

    Standard health information delivered via brochure, no active navigation components. Content includes a brochure describing services offered by CVS Health and the MinuteClinic.

06

What researchers measure

Primary outcomes

  1. Self-report attendance at first PrEP appointment

    Attendance at the first scheduled PrEP (pre-exposure prophylaxis) appointment will be assessed using self-report responses at baseline, 3 months, and 6 months. Participants will respond to the question: "Did you attend your first scheduled PrEP appointment?" with binary options (Yes/No). This will be measured by the percentage of participants responding "Yes" at each time point and will evaluate engagement with PrEP services over time.

    Time frame: Baseline, 3 months, and 6 months

Secondary outcomes

  1. PrEP Cascade Questionnaire, measured by participant survey responses

    The PrEP Cascade Questionnaire is a structured survey designed to assess participant engagement across stages of the PrEP prevention cascade (awareness, access, initiation, adherence, and retention). Each item will be scored as binary (Yes/No) or categorical (e.g., aware/not aware, initiated/not initiated, adherent/non-adherent). This will be measured by the percentage of participants meeting each cascade stage at each time point and will evaluate the progression through the PrEP cascade over time.

    Time frame: Baseline, 3 months, and 6 months

  2. Percentage of correct PrEP questions, measured by participant survey responses

    The PrEP Questionnaires is a structured survey designed to assess participant PrEP knowledge. Each item will be scored as binary (Yes/No) or categorical. This will be measured by the percentage of correct responses at each time point and will evaluate PrEP knowledge over time.

    Time frame: Baseline, 3 months, and 6 months.

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jan 2027; primary completion for Oct 2029, 33 months later.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Jan 2027, on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2025
First posted
Dec 4, 2025
StartEst.
Jan 15, 2027was Oct 2026
Primary completionEst.
Oct 2029
CompletionEst.
Oct 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 30, 2026→Jan 15, 2027
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Start date Oct 30, 2026→Jan 15, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07263048
Responsible party
Mariano Juan Kanamori Nishimura (Professor, University of Miami) — Principal investigator
First posted
Dec 4, 2025
Start date
Jan 15, 2027 (estimated)
Primary completion
Oct 2029 (estimated)
Completion
Oct 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Maria R Velazquez, MPA
Contact
mrvelazquez@med.miami.edu
305-243-1946
Mariano R Kanamori, PhD
principal investigator · University of Miami

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion